Guillain-Barre syndrome

This trial tests whether efgartigimod, a drug that lowers harmful antibody levels, can improve recovery in people with Guillain-Barré syndrome (GBS), a rare nerve condition that can cause weakness and paralysis. Adults aged 18 to 70 with recent GBS onset will receive either efgar…

Guillain-Barré syndrome (GBS) is a rare condition where the immune system attacks nerves, causing weakness that can progress to paralysis. Standard treatment is intravenous immunoglobulin (IVIg), but recovery is often slow. This phase 2 trial tests whether adding an experimental …

This study looks closely at children admitted to a hospital with acute flaccid paralysis, a condition causing sudden muscle weakness or paralysis. Researchers will collect information from routine medical care to describe the clinical features, possible risk factors, and outcomes…

This study will follow 1,550 adults with various neurological autoimmune diseases—like multiple sclerosis, myasthenia gravis, and autoimmune encephalitis—to see how these conditions progress and respond to treatments in everyday medical practice. Researchers will measure disabili…

This study will look at medical and lab factors that influence how children with Guillain-Barré syndrome recover. Researchers will follow 80 children to see which ones fully recover within 3 months. The goal is to create better ways to predict outcomes and guide treatment.